



EMBARGO: 3:00 p.m. EST (20:00 GMT), Monday, March 15, 2004
Contact: USA: Marshall Hoffman +1-703-820-2244 (O), +1-703-801-8602 (M)
or Nancy Pekarek +1-215-751-4232 (O), +1-215-778-0366 (M)
UK: Juliet Heller +44(0)-1621-86-80-8 (O), +44(0)-7946-61-61-50 (M)
Switzerland: Carlos Bauverd +41-21-646-4175 (O), +41(0)-79-327-8024 (M)
Released from London, UK, Washington, DC and Toronto, Canada

80 Million People Now Treated to Prevent Elephantiasis

Various Shots of the disease

01 00 00 Man with elephantiasis (leg) walks toward the camera (Papua New Guinea)
01 00 08 Men with elephantiasis (legs) caused by Brugia infection (India)
01 00 20 Man with elephantiasis (leg) walks toward the camera
01 00 28 Men with elephantiasis (legs) caused by Brugia infection (India)
01 00 40 Inelastic skin due to elephantiasis of the arm (Brugia infection)
01 00 47 Woman with elephantiasis of the leg
01 00 54 Men with elephantiasis (legs) at work (India)
01 01 08 Inelastic skin due to elephantiasis of the leg - c/up
01 01 11 Man with elephantiasis (legs) walking across flooded road (India)
01 01 14 Woman with elephantiasis (leg) (Ghana)
01 01 17 Man with elephantiasis (legs) walking across flooded road (India)

Mosquito and Parasite Shots

01 01 55 Mosquitos biting victims – c/up
01 02 02 Mosquito (Mansonia) larvae (+ c/up)
01 02 10 Drainage ditch (mosquito breeding site)
01 02 21 C/up ditch water and sampling for mosquito larvae
01 02 37 Mansonia egg clusters on the underside of aquatic weeds
01 02 43 Photomicrograph: infective larvae emerging from mosquito mouthparts
01 02 53 Examination of mosquito under microscope
01 03 08 Mosquito (Mansonia) larvae
01 03 16 Mosquito larvae hatch into adult

Screening for the Disease

01 03 35 Doctor takes blood sample from young boy (India)
01 03 55 Doctor examines patient
01 04 10 Doctor examining between toes (entry point of parasites causing secondary infection)
01 04 20 Night-time blood sampling (India)
01 04 40 Night-time blood sampling (Papua New Guinea)
01 04 50 Making blood smears (slides)

Treatment of the Disease

01 05 22 Ultrasonography (of hydrocoele) to locate adult worms
01 05 44 Pharmacy: distributing tablets at night (India)
01 05 56 Mother and infant taking tablets (Papua New Guinea)
01 05 59 Young boy taking tablets (Papua New Guinea)
01 06 04 Distributing drugs to community (Brazil)

Treatment of the Disease – (continued from page 1)

- 01 06 09 Pills on a plate then taken by young boy (Samoa)
- 01 06 12 Man taking tablets in doctors office (India)
- 01 06 17 Man taking tablets (Ghana)
- 01 06 20 Bag of DEC fortified salt (India)
- 01 06 33 Woman cooking with salt (India)
- 01 06 46 Washing leg of man with elephantiasis

Prevention and Extermination Efforts

- 01 07 45 Use of bednets in various communities
- 01 08 18 Various forms of mosquito repellent
- 01 08 25 Spraying ditch water using Bacillus sphaericus as a biocontrol agent (Mali)
- 01 08 56 Adding polystyrene beads to sewage pit to prevent mosquito breeding (Brazil)
- 01 09 14 Community clearing weeds (India)
- 01 09 27 Signs: Health education/community involvement (India)
- 01 09 31 Spraying with insecticide inside house to kill mosquitoes

Environment and Living Conditions

- 01 09 42 Environmental conditions for transmission: African village
- 01 09 58 Environmental conditions for transmission: Indian canals
- 01 10 04 Environmental conditions for transmission: African fishing
- 01 10 18 Rice fields in Asia
- 01 10 31 Crowd of refugees (Africa)
- 01 10 50 Crowds on the streets of town (India)
- 01 11 07 Crowds in town (Asia)
- 01 11 15 Crowds in town (Africa)

Map

- 01 11 29 Lymphatic Filariasis Endemic Countries and Territories in 2003

Albendazole Production

- 01 11 46 Albendazole production

Interview with J.P. Garnier, CEO, GlaxoSmithKline (English and French)

English

- 01 12 10 Question 1. Why did GlaxoSmithKline become so heavily involved in this elimination program?
- 01 12 46 Question 2. Why do you think that the world can eliminate lymphatic filariasis?
- 01 13 22 Question 3. What is GlaxoSmithKline's commitment to this program and how long will it take to eliminate lymphatic filariasis?

French

- 01 13 58 Question 1. Why did GlaxoSmithKline become so heavily involved in this elimination program and why do you think that the world can eliminate lymphatic filariasis?
- 01 14 40 Question 3. What is GlaxoSmithKline's commitment to this program and how long will it take to eliminate lymphatic filariasis?